Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

IRD

Opus Genetics Inc

Nov 13 • 04:00PM ET

1.85

-0.07 -3.65 %

Healthcare • Biotechnology • USA • NASD

Index	-	P/E	-	EPS (ttm)	-1.72	Insider Own	58.38%	Shs Outstand	64.54M	Perf Week	-8.87%
Market Cap	127.33M	Forward P/E	-	EPS next Y	-0.38	Insider Trans	0.00%	Shs Float	47.66M	Perf Month	-7.50%
Enterprise Value	97.58M	PEG	-	EPS next Q	-0.12	Inst Own	20.82%	Short Float	1.05%	Perf Quarter	54.17%
Income	-68.20M	P/S	8.70	EPS this Y	68.44%	Inst Trans	30.35%	Short Ratio	1.18	Perf Half Y	94.74%
Sales	14.63M	P/B	20.01	EPS next Y	44.63%	ROA	-178.28%	Short Interest	0.50M	Perf YTD	55.46%
Book/sh	0.09	P/C	4.13	EPS next 5Y	43.67%	ROE	-338.75%	52W High	2.37 -21.94%	Perf Year	58.12%
Cash/sh	0.45	P/FCF	-	EPS past 3/5Y	17.37% 24.32%	ROIC	-969.48%	52W Low	0.65 184.62%	Perf 3Y	-25.70%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	165.25% -	Gross Margin	99.66%	Volatility	8.01% 7.94%	Perf 5Y	-69.17%
Dividend TTM	-	EV/Sales	6.67	EPS Y/Y TTM	-58.14%	Oper. Margin	-254.05%	ATR (14)	0.16	Perf 10Y	-99.24%
Dividend Ex-Date	-	Quick Ratio	1.23	Sales Y/Y TTM	74.60%	Profit Margin	-466.09%	RSI (14)	43.58	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.23	EPS Q/Q	14.17%	SMA20	-7.85%	Beta	0.43	Target Price	7.71
Payout	-	Debt/Eq	0.18	Sales Q/Q	-20.38%	SMA50	1.60%	Rel Volume	1.48	Prev Close	1.92
Employees	18	LT Debt/Eq	0.18	Earnings	Nov 12 BMO	SMA200	50.67%	Avg Volume	421.38K	Price	1.85
IPO	Nov 30, 2004	Option/Short	Yes / Yes	EPS/Sales Surpr.	-92.31% 0.25%	Trades		Volume	623,387	Change	-3.65%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-29-25	Initiated	Wedbush	Outperform	$8
Oct-16-25	Initiated	Chardan Capital Markets	Buy	$9
Apr-11-25	Initiated	Craig Hallum	Buy	$6
Nov-13-24	Resumed	H.C. Wainwright	Buy	$8

Today 07:00AM	Opus Genetics Announces Dosing of First Participant in OPGx-BEST1 Phase 1/2 Gene Therapy Clinical Trial for Best Disease (GlobeNewswire)
Nov-12-25 08:30AM	Opus Genetics, Inc. (IRD) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
07:00AM	Opus Genetics Announces Financial Results for Third Quarter 2025 and Provides Corporate Update (GlobeNewswire)
Nov-06-25 05:35PM	Zymeworks Inc. (ZYME) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Opus Genetics Announces Successful FDA Meeting Supporting Advancement of OPGx-LCA5 Toward Pivotal Trial for LCA5-Related Inherited Retinal Disease (GlobeNewswire)
07:00AM	Loading…
07:00AM	Opus Genetics Announces $23 Million Registered Direct Offering (GlobeNewswire)
Nov-05-25 10:00AM	Analysts Estimate Alvotech (ALVO) to Report a Decline in Earnings: What to Look Out for (Zacks)
07:40AM	Fortrea Holdings Inc. (FTRE) Q3 Earnings Lag Estimates (Zacks)
Nov-04-25 05:15PM	Amgen (AMGN) Q3 Earnings and Revenues Beat Estimates (Zacks)
04:01PM	Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
10:00AM	Opus Genetics, Inc. (IRD) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
Nov-03-25 08:00AM	Opus Genetics Featured on Good Morning America Spotlighting Breakthrough Gene Therapy Restoring Sight in Patients with Inherited Blindness (GlobeNewswire) -6.96%
Oct-14-25 08:00AM	Opus Genetics to Participate in Chardan's 9th Annual Genetic Medicines Conference (GlobeNewswire)
Oct-02-25 08:00AM	Opus Genetics to Present at Upcoming Medical and Industry Conferences in October 2025 (GlobeNewswire)
Oct-01-25 12:00PM	Are You Looking for a Top Momentum Pick? Why Opus Genetics, Inc. (IRD) is a Great Choice (Zacks) +9.09%
07:00AM	Loading…
Sep-30-25 07:00AM	Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5) (GlobeNewswire) -7.82%
Sep-16-25 03:42AM	Zacks.com featured highlights include Sally Beauty, Broadstone Net Lease and Opus Genetics (Zacks)
Sep-15-25 03:00PM	The Under $20 Breakout Trio Investors Shouldn't Ignore (Zacks)
Sep-12-25 08:00AM	Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-04-25 08:00AM	Opus Genetics Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions (GlobeNewswire)
Sep-03-25 08:00AM	Opus Genetics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Sep-02-25 08:00AM	Opus Genetics Appoints Rob Gagnon as Chief Financial Officer (GlobeNewswire)
Aug-27-25 08:00AM	Opus Genetics Inherited Retinal Disease Programs Featured at Medical and Industry Conferences in September (GlobeNewswire)
Aug-18-25 08:00AM	Opus Genetics Announces FDA Clearance of IND Application for Gene Therapy Candidate OPGx-BEST1 (GlobeNewswire)
Aug-13-25 05:40PM	Opus Genetics, Inc. (IRD) Reports Q2 Loss, Lags Revenue Estimates (Zacks) +7.27%
04:30PM	Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate Update (GlobeNewswire)
Aug-07-25 08:25AM	Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
Aug-05-25 08:00AM	Opus Genetics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference (GlobeNewswire)
Jul-23-25 08:00AM	Opus Genetics and the Global RDH12 Alliance Partner to Advance RDH12 Gene Therapy for Inherited Childhood Blindness (GlobeNewswire)
Jul-10-25 09:31AM	Vir Biotechnology (VIR) Soars 11.9%: Is Further Upside Left in the Stock? (Zacks)
04:30PM	Loading…
Jul-03-25 04:30PM	Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-26-25 06:55AM	Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia (GlobeNewswire) +5.13%
Jun-23-25 08:00AM	Opus Genetics Awarded Non-Dilutive Funding from the RD Fund to Support Preclinical Development of OPGx-MERTK Program (GlobeNewswire)
Jun-02-25 08:00AM	Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions (GlobeNewswire) +9.60%
May-15-25 09:15AM	Opus Genetics, Inc. (IRD) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Opus Genetics Announces Financial Results for First Quarter 2025 and Provides Corporate Update (GlobeNewswire)
May-14-25 06:55PM	Bluebird Bio (BLUE) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
May-13-25 08:45AM	Humacyte, Inc. (HUMA) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
May-12-25 08:00AM	Opus Genetics Announces Presentations on Inherited Retinal Disease Programs at Medical Conferences in May (GlobeNewswire)
May-08-25 09:25AM	Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
May-06-25 08:00AM	Opus Genetics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OPGx-LCA5 Gene Therapy Candidate (GlobeNewswire)
May-05-25 08:00AM	Opus Genetics Announces Presentation of OPGX-LCA5 Gene Therapy Data at ARVO; 12 Month Phase 1/2 Results Support Potential to Restore to Meaningful Vision (GlobeNewswire)
May-02-25 10:00AM	Earnings Preview: Opus Genetics, Inc. (IRD) Q1 Earnings Expected to Decline (Zacks)
Apr-15-25 10:36AM	PRISM MarketView Spotlights Opus Genetics in New Q&A with CEO George Magrath (GlobeNewswire)
Apr-11-25 03:47PM	Founder Mina Sooch Issues Open Letter to Opus Genetics Stockholders Following Withdrawal of the Restore Value Slate Amid Dilutive Financing and Governance Concerns (GlobeNewswire)
Apr-08-25 08:00AM	Opus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases (GlobeNewswire) -11.50%
Apr-07-25 08:00AM	Opus Genetics Files Definitive Proxy Statement and Sends Letter to Stockholders Highlighting the Company's Transformation and Progress (GlobeNewswire)
Apr-02-25 08:00AM	Opus Genetics to Participate in Upcoming Investor Conference in April (GlobeNewswire)
Mar-31-25 08:20AM	Opus Genetics Announces Financial Results for Full Year 2024 (GlobeNewswire)
Mar-21-25 05:03PM	Restore Value Slate Led by Mina Sooch Files Preliminary Proxy Materials for the Election of Six Highly Qualified Directors at the 2025 Annual Meeting of Opus Genetics (GlobeNewswire) +9.57% -8.73%
09:30AM	Opus Genetics Announces Presentation on Phentolamine Ophthalmic Solution 0.75% in Dim Light Disturbances at World Cornea Congress IX (GlobeNewswire)
09:11AM	Opus Genetics Announces Pricing of Public Offering and Concurrent Private Placement with Proceeds of Over $20 Million (GlobeNewswire)
Mar-19-25 03:56PM	Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-05-25 08:00AM	Opus Genetics Announces Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting (GlobeNewswire)
Feb-26-25 08:00AM	Opus Genetics Announces FDA Fast Track and Enrollment Updates for Phentolamine Ophthalmic Solution 0.75% Programs (GlobeNewswire)
Feb-18-25 07:30AM	Opus Genetics Announces Updates on OPGx-LCA5 Clinical Program (GlobeNewswire)
Feb-07-25 09:15AM	Shareholder Group Led by Founder Mina Sooch Nominates Majority Slate of Director Candidates to the Board of Opus Genetics, Inc. (GlobeNewswire) -5.74%
Dec-19-24 08:00AM	Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of APX3330 in Diabetic Retinopathy (GlobeNewswire) +18.93%
Dec-03-24 08:00AM	Opus Genetics to Host Virtual KOL Event on OPGx-LCA5 as a Treatment for LCA5-Associated Inherited Retinal Disease on December 11, 2024 (GlobeNewswire) +5.22%
Nov-14-24 06:40AM	Opus Genetics reinstated with a Buy at H.C. Wainwright (TipRanks)
Nov-12-24 08:00AM	Opus Genetics Announces Financial Results for Third Quarter 2024 and Provides Corporate Update (GlobeNewswire)
07:59AM	Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-25-24 12:00PM	The RD Fund Announces Ocuphire Pharma's Acquisition of Opus Genetics (PR Newswire)
Oct-23-24 05:31PM	Ocuphire Pharma Merges with Opus Genetics, Renamed Opus Genetics (TipRanks) -12.03%
Oct-22-24 04:05PM	Ocuphire Pharma Announces Acquisition of Opus Genetics (GlobeNewswire)
Sep-30-24 08:00AM	Ocuphire Pharma Announces Publication of Full Phase 3 Results of Phentolamine Ophthalmic Solution 0.75% for Pharmacologically-Induced Mydriasis in Ophthalmology (GlobeNewswire)
Sep-05-24 08:43PM	UPDATE Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Presbyopia (GlobeNewswire)
08:00AM	Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Presbyopia (GlobeNewswire)
Aug-13-24 08:00AM	Ocuphire Pharma Announces Financial Results for Second Quarter 2024 and Provides Corporate Update (GlobeNewswire) -20.85%
Aug-08-24 08:00AM	Ocuphire Pharma to Present at Two Investor Conferences in August (GlobeNewswire) +6.10%
Jul-10-24 08:00AM	Ocuphire Pharma to Highlight APX3330 for Diabetic Retinopathy at Two Scientific Meetings in July (GlobeNewswire) +6.45%
Jun-06-24 07:57AM	Ocuphire Pharma Announces Presentations on the Development of APX3330 for Diabetic Retinopathy at Retina Meetings in June (GlobeNewswire)
May-10-24 01:53PM	OCUP Stock Earnings: Ocuphire Pharma Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace) -12.24%
08:00AM	Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update (GlobeNewswire)
May-06-24 08:00AM	Ocuphire Pharma Announces Presentation on APX3330 at the ARVO 2024 Annual Meeting (GlobeNewswire)
May-03-24 08:00AM	Ocuphire Pharma to Present at the Aegis Virtual Conference (GlobeNewswire) +7.57%
Apr-22-24 08:00AM	Ocuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual Meeting (GlobeNewswire) -8.76%
Apr-11-24 10:03AM	First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery (GlobeNewswire)
Apr-01-24 07:14AM	Ocuphire Announces the U.S. Commercial Launch of RYZUMVl (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris (GlobeNewswire) +10.95%
Mar-15-24 11:53AM	OCUP Stock Earnings: Ocuphire Pharma Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace)
Mar-09-24 01:09PM	12 Most Undervalued Biotech Stocks To Buy According To Hedge Funds (Insider Monkey)
Mar-08-24 08:00AM	Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate Update (GlobeNewswire) -16.39%
Mar-04-24 08:18AM	Ocuphire (OCUP) to Report Q4 Earnings: What's in the Cards? (Zacks)
Feb-23-24 08:00AM	Ocuphire Pharma to Present in the BIO CEO & Investor Conference (GlobeNewswire)
Feb-15-24 04:10PM	Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-14-24 08:00AM	Ocuphire Pharma Strengthens Leadership Team with Key Appointments (GlobeNewswire)
Feb-05-24 08:00AM	Ocuphire Pharma Announces Presentation on APX3330 at the Annual Angiogenesis, Exudation, and Degeneration 2024 Conference (GlobeNewswire)
Jan-24-24 04:10PM	Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-11-24 07:41AM	Here's Why You Should Invest in Ocuphire Pharma (OCUP) Now (Zacks) -7.81%
Jan-04-24 08:00AM	Ocuphire Pharma Receives FDA Agreement Under Special Protocol Assessment for LYNX-2 Phase 3 Trial of Phentolamine Ophthalmic Solution for the Treatment of Decreased Visual Acuity under Dim (mesopic) Light Conditions (GlobeNewswire)
Nov-30-23 08:00AM	Ocuphire Pharma Announces Presentation at Ophthalmology Innovation Summit (OIS) XIII (GlobeNewswire) +11.31%
Nov-27-23 04:38PM	Ocuphire Pharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer (GlobeNewswire)
Nov-13-23 08:00AM	Ocuphire Pharma Announces Financial Results for Third Quarter 2023 and Provides Corporate Update (GlobeNewswire)
Nov-02-23 08:00AM	Ocuphire Pharma Announces Successful End-of-Phase 2 Meeting with FDA for Oral APX3330 in Diabetic Retinopathy (GlobeNewswire)
Nov-01-23 04:52PM	Ocuphire Pharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:05AM	Ocuphire Pharma Announces Appointment of George Magrath, M.D., M.B.A., M.S., as Chief Executive Officer and Director (GlobeNewswire)
Oct-26-23 08:00AM	Ocuphire Pharma to Present at AAO 2023 and Eyecelerator Retina Showcase (GlobeNewswire)
Oct-06-23 08:00AM	Ocuphire Pharma to Present at Euretina and Retina Society Conferences in October (GlobeNewswire)
Sep-27-23 08:00AM	Viatris and Ocuphire Pharma Announce FDA Approval of RYZUMVl (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (e.g., Phenylephrine) or Parasympatholytic (e.g., Tropicamide) Agents (PR Newswire) -5.97%

Opus Genetics, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders. The company was founded by Mina Patel Soouch and Alan R. Meyer in February 2018 and is headquartered in Durham, NC.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Magrath George	Chief Executive Officer	Dec 26 '24	Buy	0.98	100,000	97,600	599,150	Dec 30 04:26 PM
YERXA BENJAMIN R	President	Nov 21 '24	Buy	0.98	10,000	9,834	342,800	Nov 25 04:18 PM
Magrath George	Chief Executive Officer	Nov 15 '24	Buy	1.01	90,294	91,215	483,244	Nov 19 04:08 PM
Magrath George	Chief Executive Officer	Nov 18 '24	Buy	1.02	9,706	9,943	492,950	Nov 19 04:08 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IRD

Opus Genetics Inc

Upgrade your FINVIZ experience